Journal article
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study)
Abstract
Background: Tofacitinib is a rapidly acting Janus kinase (JAK) inhibitor with increasing evidence of effectiveness in patients with acute severe ulcerative colitis (ASUC). However, there are scarce prospective data analyzing the efficacy and rapidity of action in hospitalized ASUC.
Methods: The TRIUMPH study is a prospective open-label interventional trial of tofacitinib in hospitalized patients with ASUC conducted in 5 hospitals across Canada …
Authors
Narula N; Pray C; Hamam H; Peerani F; Hansen T; Bessissow T; Bressler B; Arun A; Schmit M; Castelli J
Journal
Crohn's & Colitis 360, Vol. 7, No. 1,
Publisher
Oxford University Press (OUP)
Publication Date
December 30, 2024
DOI
10.1093/crocol/otaf013
ISSN
2631-827X